Global Healthy Living Foundation has 12 posters and Polymyalygia Rheumataca, Psoriasis and RA Research at American College of ...

Polymyalgia rheumatica (PMR) is a common inflammatory condition affecting elderly people and involving the girdles. [1] The mainstay of treatment is oral glucocorticoids (GC), with the recent BSR ...

Veeva Systems today announced that Boehringer Ingelheim is the latest global top 20 biopharma company to commit to moving to Veeva Vault ...

The Lupus Foundation of America (LFA), along with numerous researchers funded by the Foundation, will present novel lupus discoveries as part of the American College of Rheumatology Convergence 2024 ...

This observation suggests that a close follow-up in the first days after diagnosis and treatment initiation is important to ensure that the patient is administered an adequate prednisone dosage.

PUDUCHERRY: Urging the Lieutenant Governor to address claims of a lack of proper machinery in manufacturing corrective ...

These included older age, use of certain classes of disease-modifying anti-rheumatic drugs (DMARDs), and ... Sjögren's syndrome, and polymyalgia rheumatica. RA accounted for more than one-third ...

Before I even finish my story, he says: “Polymyalgia rheumatica. I’ve had it ... diseases require much higher doses of prednisone initially and then require other medications to control the disease., ...

Treatment for viral arthritis is normally focused on pain ... Other characteristics of sarcoidosis that help to distinguish ...

Q3 2024 Earnings Call Transcript October 29, 2024 Novartis AG beats earnings expectations. Reported EPS is $2.06, expectations were $1.96. Operator: Good morning and good afternoon, and welcome to the ...

Background: Glucocorticoids (GC) are the cornerstone of the treatment of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA), but they are associated with several adverse events (AEs).

Background Glucocorticoids are the cornerstone treatment of polymyalgia rheumatica (PMR) but induce adverse events. Objectives To evaluate the efficacy and safety of first-line tocilizumab in PMR.